ME00592A - Method of treating thermoregulatory disfunction with paroxetine - Google Patents

Method of treating thermoregulatory disfunction with paroxetine

Info

Publication number
ME00592A
ME00592A MEP-37/09A MEP3709A ME00592A ME 00592 A ME00592 A ME 00592A ME P3709 A MEP3709 A ME P3709A ME 00592 A ME00592 A ME 00592A
Authority
ME
Montenegro
Prior art keywords
paroxetine
heat
waves
menopause
disfunction
Prior art date
Application number
MEP-37/09A
Other languages
English (en)
Croatian (hr)
Inventor
Patricia Allison Tewes Richards
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39030027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00592(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME00592B publication Critical patent/ME00592B/me
Publication of ME00592A publication Critical patent/ME00592A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na postupak za liječenje pacijenata koji su oboljeli od termoregulacione disfunkcije, posebno nastupa vreline i vrelih talasa povezanih sa hormonalnim promjenama usled prirodne menopauze (bilo muškaraca bilo žena) ili usled hemijski ili hiruški indukovane menopauze. Postupak se takođe primjenjuje za liječenje nastupa vreline, vrelih talasa ili noćnog znojenja povezanih sa stanjem bolesti koje remeti normalnu hormonalnu regulaciju tjelesne temperature.
MEP-37/09A 2006-08-04 2007-07-31 Method of treating thermoregulatory disfunction with paroxetine ME00592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/499,586 US20080033050A1 (en) 2006-08-04 2006-08-04 Method of treating thermoregulatory disfunction with paroxetine
PCT/US2007/017062 WO2008019010A2 (en) 2006-08-04 2007-07-31 Method of treating thermoregulatory disfunction with paroxetine

Publications (2)

Publication Number Publication Date
ME00592B ME00592B (me) 2011-12-20
ME00592A true ME00592A (en) 2011-12-20

Family

ID=39030027

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-37/09A ME00592A (en) 2006-08-04 2007-07-31 Method of treating thermoregulatory disfunction with paroxetine

Country Status (27)

Country Link
US (7) US20080033050A1 (bs)
EP (2) EP2719385B1 (bs)
JP (2) JP5846717B2 (bs)
KR (3) KR20090040453A (bs)
CN (1) CN101505759A (bs)
AU (1) AU2007282065B2 (bs)
BR (1) BRPI0715087A2 (bs)
CA (1) CA2659577C (bs)
CY (2) CY1120867T1 (bs)
DK (2) DK2068881T3 (bs)
ES (2) ES2698207T3 (bs)
HR (2) HRP20181893T1 (bs)
HU (2) HUE040481T2 (bs)
IL (1) IL196844A (bs)
LT (2) LT2719385T (bs)
ME (1) ME00592A (bs)
MX (1) MX2009001275A (bs)
NO (1) NO343176B1 (bs)
NZ (1) NZ574735A (bs)
PL (2) PL2719385T3 (bs)
PT (2) PT2068881T (bs)
RS (2) RS57980B1 (bs)
RU (1) RU2478379C2 (bs)
SG (1) SG176452A1 (bs)
SI (2) SI2719385T1 (bs)
UA (1) UA96770C2 (bs)
WO (1) WO2008019010A2 (bs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
SG11201708162UA (en) * 2015-04-07 2017-11-29 Meiji Co Ltd Hot flash-suppressing agent
KR102817311B1 (ko) 2016-09-29 2025-06-09 (주)아모레퍼시픽 젖산을 유효성분으로 포함하는 열성홍조 개선용 건강식품 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
JPH0837567A (ja) 1994-07-26 1996-02-06 Olympus Optical Co Ltd 情報記録媒体及び情報再生装置
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
GB9710004D0 (en) * 1997-05-17 1997-07-09 Knoll Ag Chemical process
EP0986389B1 (en) * 1997-05-29 2004-10-13 Smithkline Beecham Corporation Novel process
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
US6133277A (en) * 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
AU3306399A (en) 1998-03-02 1999-09-20 Eli Lilly And Company Fluoxetine hydrochloride for decreasing hot flashes
HUP0101215A3 (en) * 1998-03-16 2002-05-28 Smithkline Beecham Plc Chrystalline form of paroxetine
US6699882B2 (en) * 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US20030028027A1 (en) * 1998-04-09 2003-02-06 Smithkline Beecham Plc Paroxetine maleate
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
US6168805B1 (en) * 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
US6369051B1 (en) * 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
EP1347960B1 (en) * 2001-01-04 2004-11-17 Ferrer Internacional, S.A. Process for preparing (+) trans-4-p-fluorophenyl-3-hydroxymethyl-1
DE20100529U1 (de) 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1266659A1 (en) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6956121B2 (en) * 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
ITMI20022344A1 (it) * 2002-11-05 2004-05-06 Biofarm Srl Prodotto in pellicola a rapida dissoluzione in acqua, per il trattamento del latte con batteri e/o enzimi.
TWI267838B (en) * 2003-01-03 2006-12-01 Lite On It Corp Method to detect the type of optical disk
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
WO2007043057A2 (en) * 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Also Published As

Publication number Publication date
CY1120867T1 (el) 2019-12-11
KR20140098865A (ko) 2014-08-08
SG176452A1 (en) 2011-12-29
UA96770C2 (uk) 2011-12-12
US8859576B2 (en) 2014-10-14
RS58046B1 (sr) 2019-02-28
US20140249182A1 (en) 2014-09-04
US20170165251A1 (en) 2017-06-15
MX2009001275A (es) 2009-04-16
DK2719385T3 (en) 2018-12-10
JP2009545593A (ja) 2009-12-24
LT2068881T (lt) 2018-12-10
LT2719385T (lt) 2018-12-27
IL196844A0 (en) 2009-12-24
EP2719385B1 (en) 2018-08-29
JP5846717B2 (ja) 2016-01-20
HUE040481T2 (hu) 2019-03-28
PT2719385T (pt) 2018-12-04
PL2719385T3 (pl) 2019-06-28
BRPI0715087A2 (pt) 2015-02-10
DK2068881T3 (en) 2018-12-10
WO2008019010A3 (en) 2008-12-24
EP2068881B1 (en) 2018-08-22
ME00592B (me) 2011-12-20
AU2007282065A1 (en) 2008-02-14
PL2068881T3 (pl) 2019-04-30
US9393237B2 (en) 2016-07-19
US8658663B2 (en) 2014-02-25
HRP20181893T1 (hr) 2019-01-11
EP2068881A2 (en) 2009-06-17
US20180036299A1 (en) 2018-02-08
HUE040099T2 (hu) 2019-02-28
US20200268733A9 (en) 2020-08-27
CN101505759A (zh) 2009-08-12
US20090275615A1 (en) 2009-11-05
US20150335631A1 (en) 2015-11-26
ES2698207T3 (es) 2019-02-01
NO343176B1 (no) 2018-11-26
WO2008019010A2 (en) 2008-02-14
US20080033050A1 (en) 2008-02-07
EP2068881A4 (en) 2009-09-30
RU2478379C2 (ru) 2013-04-10
CY1120902T1 (el) 2019-12-11
NO20090639L (no) 2009-02-25
AU2007282065B2 (en) 2013-05-09
KR20090040453A (ko) 2009-04-24
JP5895009B2 (ja) 2016-03-30
KR20150132888A (ko) 2015-11-26
PT2068881T (pt) 2018-11-29
ES2699298T3 (es) 2019-02-08
HRP20181925T1 (hr) 2019-01-11
RU2009107739A (ru) 2010-09-10
SI2068881T1 (sl) 2019-01-31
CA2659577A1 (en) 2008-02-14
SI2719385T1 (sl) 2019-01-31
JP2014077023A (ja) 2014-05-01
IL196844A (en) 2015-11-30
NZ574735A (en) 2011-03-31
RS57980B1 (sr) 2019-01-31
US8946251B2 (en) 2015-02-03
EP2719385A1 (en) 2014-04-16
US20140235674A1 (en) 2014-08-21
CA2659577C (en) 2015-11-24

Similar Documents

Publication Publication Date Title
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
DK2200616T3 (da) Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
EP1933873A4 (en) METHOD AND COMPOSITION FOR USE IN THE TREATMENT OF PATIENTS WITH AUTOANTICODRIVER POSITIVE SUFFERING
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
WO2008156685A3 (en) Tendon stem cells
PL3746126T3 (pl) Sposoby i kompozycje do leczenia bezdechu sennego lub zwykłego chrapania
PH12013501790A1 (en) Uses of dpp~iv inhibitors
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
ATE494888T1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
JO3358B1 (ar) معالجات حساسية العيون
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ME00592A (en) Method of treating thermoregulatory disfunction with paroxetine
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
NO20072285L (no) S-mirtazapin for behandling av hetetokter
EP2001488A4 (en) PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
NO20073941L (no) Dihydroimidazotiazolderivater
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
EP1812078A4 (en) KINASEHEMMER FOR THE TREATMENT OF DIABETES AND ADIPOSITAS
Roche et al. Orbital exenteration in periorbital malignancies
Hess et al. Modified preparation of the neurovascular bundle in male to female transgender patients